Skip to content

Effect of Fermented Rice Bran Powder on the Immunologic Function in the Healthy Adults

Effect of Fermented Rice Bran Powder on the Immunologic Function in the Healthy Adults

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
CRIS
Registry ID
KCT0000536
Enrollment
80
Registered
2012-09-14
Start date
2012-09-17
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Fermented rice bran powder group: The main ingredient is rice bran, 502.5mg/1 hardcapsule (Fermented rice bran powder 500mg /1 hardcapsule), 6 capsules a day with water. Placebo

Sponsors

Erom
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Men and women aged 25 to 70 years 2) People who signed the informed consent form before participating in the study 3) Healthy people whose peripheral blood WBC count = 4X1000 and < 8X1000 cells/ul at screening

Exclusion criteria

Exclusion criteria: 1) subjects with clinically significant cardiovascular, immune, infectious, or neoplastic disease currently 2) subjects with a known history of myocardial infarction or cerebrovascular disease within the last 6 months 3) subjects who are under treatment for uncontrolled hypertension, diabetes, thyroid disease etc. (However, subjects can be involved in the study based on doctor’s assessment) 4) subjects whose AST(GOT) or ALT(GPT) level is more than three times higher than the upper limit of the normal range 5) subjects whose creatinine level is more than twice higher than the upper limit of the normal range 6) subjects who have regularly taken functional foods or drugs within the last 3 months or suffered from infection within the last 3 months prior to the first visit of the study 7) subjects who are pregnant or scheduled for pregnancy 8) subjects with a serious mental illness 9) subjects who are scheduled for another study during this study period 10) subjects with any other health concerns

Design outcomes

Primary

MeasureTime frame
NK cell activity;WBC count;IFN-?;IL-2, 4, 10, 12;TNF-a

Secondary

MeasureTime frame
adverse events ;clinical pathological tests (hematologic test, blood chemical test, urine test), ;vital sign (blood pressure, pulse)

Countries

Korea, Republic of

Contacts

Public ContactJi-Young Choi

Hanyang University

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Mar 20, 2026